Agranulocytosis and Ranitidine
Authors: Louis O. BRENNER
Journal: Annals of Internal Medicine (1986)

Letters and Corrections1 June 1986Agranulocytosis and RanitidineLouis O. BRENNER, M.D.Louis O. BRENNER, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-104-6-896_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Ranitidine is a histamine-2 receptor antagonist that has been approved for use in the United States since 1983. It is more potent than Cimetidine and has not been reported to cause complications, especially agranulocytosis (1).An 86-year-old white woman was hospitalized on 8 May 1985 with fever. Seven weeks earlier she had had an uncomplicated takedown of a colostomy. At that time, abnormal hepatic function tests and hyperglycemia were noted, but a complete blood count and differential were normal. Ten days before the current admission she was treated with ranitidine, 150 mg twice daily, and with an...References1. ZELDISFREIDMANISSELBACHER JLK. Ranitidine: a new H2 receptor antagonist. TV Engl J Med. 1983;309:1368-73. CrossrefMedlineGoogle Scholar2. UFBERGBROOKSBOSANACKINTZEL MCPJ. Transient neutropenia in a patient receiving Cimetidine. Gastroenterology. 1977;73:635-8. CrossrefMedlineGoogle Scholar3. GREENBLATTSELLERSSHADER DER. Drug disposition in old age. N Engl J Med. 1982;306:1081-8. CrossrefMedlineGoogle Scholar4. YOUNGDANESHMENDROBERTS CTC. Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine. Gut. 1982;23:819-23. CrossrefMedlineGoogle Scholar5. GreeneSzegoAmflowHooper DPJJ. The effect of age on ranitidine pharmacodynamics. J Clin Pharmacol Ther. 1986; 39:300-5. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Harrisburg Hospital Harrisburg, PA 17110 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByLa leucocitopenia en pacientes tratados con clozapina puede estar inducida por otros fármacos: una serie clinicaLeukopenia in clozapine treated patients may be induced by other drugs: a case seriesThrombocytopenia Secondary to Prophylactic Use of Ranitidine HydrochlorideSafety of acid-suppressing drugsRCimetidine-Induced Myelosuppression After Bone Marrow TransplantationMechanism of Ranitidine Associated AnemiaReversible Hematologic Suppression during Ranitidine TreatmentAgranulocytosis after ranitidine administrationRanitidine Fails to Suppress the Growth in vitro of Haemopoietic Progenitors from Human Peripheral Blood or Bone MarrowHaematological Adverse Effects of Histamine H2-Receptor AntagonistsDrug-Induced AgranulocytosisGastrointestinal drugsSafety perspectives on parenteral H2-receptor antagonistsClinically Important Adverse Effects and Drug Interactions with H 2 -Receptor Antagonists: An UpdateDrug points: Cricopharyngeal dyskinesia induced by prochlorperazineDrug points: Ranitidine induced granulocytopeniaDrug points: High dose co-trimoxazole for patients receiving haemodialysisDrug points: Captopril related hyperpigmentationGastrointestinal drugs 1 June 1986Volume 104, Issue 6Page: 896-897KeywordsBone marrowColostomyComplete blood countFeversHyperglycemia Issue Published: 1 June 1986 PDF DownloadLoading ...